ClinicalTrials.gg
RecruitingNCT07848750Updated Sep 30, 2026

InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma

An observational study in Hepatocellular Carcinoma, sponsored by Beijing Municipal Administration of Hospitals. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Beijing Municipal Administration of Hospitals · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
243rd of 275
40 · median 300
Started
2026
with 97 others
Observational
275 of 1,314
120 open now
Primary completion
2026-12
later than 301 of 560 live
Registered
1,303rd of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 243rd largest by planned enrollment of the 275 observational ones that give a count, is one of 98 that started in 2026, is one of 275 observational ones, reaches primary completion later than 301 of the 560 other live ones, and was the 1,303rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

483 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This prospective observational case-control study evaluates the InstaSure™ Non-Invasive Finger-Press Test for hepatocellular carcinoma (HCC). The study plans to enroll 40 participants, including 30 patients with HCC, 5 patients with benign liver disease, and 5 healthy controls. Finger-tip skin cell samples will be collected non-invasively and tested for HCC-associated CCND1 and CDKN2A/P16 eccDNA signals. The primary objective is to preliminarily evaluate the sensitivity and specificity of the test in distinguishing patients with HCC from non-HCC controls. The study will also assess the feasibility of the testing procedure and explore the association between eccDNA signals and clinical characteristics of HCC, providing preliminary data for subsequent larger-scale clinical studies.

Read the detailed description

The study will enroll 40 participants from Beijing Ditan Hospital, Capital Medical University, including 30 patients with hepatocellular carcinoma (HCC), 5 patients with benign liver disease, and 5 healthy controls. HCC will be confirmed by histopathological diagnosis or clinical imaging diagnosis according to established diagnostic criteria. Finger-tip skin cell samples will be collected using a non-invasive finger-press procedure and tested with the InstaSure™ test for HCC-associated CCND1 and CDKN2A/P16 eccDNA signals. Test results will be compared with the clinical reference diagnosis to estimate sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and the Youden index. The study will also evaluate sampling convenience, testing time, and clarity of result interpretation, and explore associations between eccDNA signals and HCC clinical characteristics such as tumor stage, tumor size, and AFP level. The findings will be used as exploratory evidence to support sample-size estimation and procedural optimization for subsequent larger-scale clinical studies.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Hepatocellular Carcinoma
  • HCC
  • Liver Cancer
  • Finger-Press Test
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of adults aged 18 years or older recruited from the outpatient and inpatient populations of the Liver Disease Center at Beijing Ditan Hospital, as well as hospital staff. The study includes three groups: participants with hepatocellular carcinoma (HCC), participants with benign liver disease without HCC, and healthy controls without a history of liver disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

HCC Group:

  • Age ≥18 years, with no restriction on sex.
  • Primary hepatocellular carcinoma (HCC) confirmed by histopathology or clinical imaging according to the diagnostic criteria specified in the National Health Commission Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2026 Edition).

Benign Liver Disease Group:

* Age ≥18 years, with no restriction on sex, with a clinical diagnosis of benign liver disease and hepatocellular carcinoma (HCC) excluded.

Healthy Control Group:

  • Age ≥18 years, with no restriction on sex.
  • No history of liver disease, with normal liver function tests and liver ultrasonography.

Exclusion criteria

Exclusion Criteria:

HCC Group:

  • History or current diagnosis of other confirmed , except for malignancies treated with curative intent and without recurrence for more than 5 years.
  • Pregnant or breastfeeding women.
  • Severe systemic diseases, including but not limited to severe cardiac, pulmonary, or renal insufficiency, or uncontrolled acute systemic infection.
  • Receipt of blood transfusion, therapy, or other interventions that may significantly affect interpretation of the test results within 1 month before enrollment.
  • Conditions affecting standardized fingertip sampling, including but not limited to severe skin lesions, fingertip injury, or inability to complete the standardized sampling procedure.
  • Poor compliance or inability to understand the study, cooperate with study procedures, or complete the study procedures as expected.
  • Any other condition that, in the investigator's judgment, may affect interpretation of the study results or participant safety.
  • Receipt of chemotherapy within 3 months before enrollment, or receipt within 1 month before enrollment of other anticancer treatment that may affect interpretation of nucleic acid signal testing results, including but not limited to targeted therapy, immunotherapy, or tumor radiotherapy.

Benign Liver Disease Group:

  • History or current diagnosis of a pathologically confirmed malignancy, except for malignancies treated with curative intent and without recurrence for more than 5 years.
  • Pregnant or breastfeeding women.
  • Severe cardiac, pulmonary, or renal insufficiency, including (NYHA) functional class III or higher heart failure or chronic kidney disease requiring regular dialysis.
  • Severe infection or active bleeding.
  • Mental or cognitive impairment resulting in inability to understand or sign the form.
  • Current participation in another interventional clinical trial.

Healthy Control Group:

  • History or current diagnosis of a pathologically confirmed malignancy, except for malignancies treated with curative intent and without recurrence for more than 5 years.
  • Pregnant or breastfeeding women.
  • Severe cardiac, pulmonary, or renal insufficiency, including New York Heart Association (NYHA) functional class III or higher heart failure or chronic kidney disease requiring regular dialysis.
  • Severe infection or active bleeding.
  • Mental or cognitive impairment resulting in inability to understand or sign the informed consent form.
  • Current participation in another interventional clinical trial.
  • Recent history of liver disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • HCC Group

    Participants with hepatocellular carcinoma (HCC) confirmed by histopathology or clinical imaging according to established diagnostic criteria. A total of 30 participants are planned for this group.

    Diagnostic Test: InstaSure™ Non-Invasive Finger-Press Test

  • Benign Liver Disease Group

    Participants with benign liver disease and without evidence of hepatocellular carcinoma. A total of 5 participants are planned for this group.

    Diagnostic Test: InstaSure™ Non-Invasive Finger-Press Test

  • Healthy Control Group

    Healthy participants without known liver disease or hepatocellular carcinoma. A total of 5 participants are planned for this group.

    Diagnostic Test: InstaSure™ Non-Invasive Finger-Press Test

Interventions

  • Diagnostic testInstaSure™ Non-Invasive Finger-Press Test

    Finger-tip skin cell samples are collected non-invasively using a finger-press procedure and tested for HCC-associated CCND1 and CDKN2A/P16 eccDNA signals. Test results are compared with the clinical reference diagnosis to evaluate the ability of the test to distinguish participants with HCC from non-HCC controls.

    Also known as: InstaSure™ HCC-Associated CYCLIN D1 & CDKN2A/P16 eccDNA Finger-Press Point-of-Care Screening Test

06

What researchers measure

Primary outcomes

  1. Diagnostic Performance of the InstaSure™ Non-Invasive Finger-Press Test for HCC

    Diagnostic performance of the InstaSure™ test for distinguishing participants with HCC from non-HCC controls will be evaluated using sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy, with the clinical reference diagnosis used as the reference standard.

    Time frame: Day 1 (at the time of study testing)

Secondary outcomes

  1. Area Under the Receiver Operating Characteristic Curve (AUC)

    The area under the receiver operating characteristic curve (AUC) will be calculated to evaluate the ability of the InstaSure™ test to discriminate participants with HCC from non-HCC controls.

    Time frame: Day 1 (at the time of study testing)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2026
First posted
Sep 30, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848750
Lead sponsor
Beijing Municipal Administration of Hospitals
Responsible party
Minghui Li (Head of Department, Beijing Municipal Administration of Hospitals) — Principal investigator
First posted
Sep 30, 2026
Start date
Jun 30, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Minghui Li, Dr
Contact
wuhm2000@sina.com
+8613693259096
Lu Zhang, Dr
Contact
zhanglu1218@126.com
+8613581975577

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion